ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
7.65
-0.11 (-1.42%)
Dec 20, 2024, 4:00 PM EST - Market closed
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 61 employees as of December 31, 2023. The number of employees increased by 37 or 154.17% compared to the previous year.
Employees
61
Change (1Y)
37
Growth (1Y)
154.17%
Revenue / Employee
$158,630
Profits / Employee
-$3,116,475
Market Cap
465.79M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Auna S.A. | 14,958 |
Talkspace | 472 |
Sangamo Therapeutics | 405 |
Xeris Biopharma Holdings | 377 |
EyePoint Pharmaceuticals | 121 |
Theravance Biopharma | 99 |
Semler Scientific | 92 |
PureTech Health | 90 |
ABVX News
- 4 weeks ago - Abivax Establishes an At-the-Market (ATM) Program on Nasdaq - GlobeNewsWire
- 5 weeks ago - Abivax presents third quarter 2024 key financial information - GlobeNewsWire
- 5 weeks ago - Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax - GlobeNewsWire
- 2 months ago - Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewsWire
- 2 months ago - Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease - GlobeNewsWire
- 2 months ago - Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance - GlobeNewsWire
- 3 months ago - Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 - GlobeNewsWire
- 3 months ago - Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model - GlobeNewsWire